A study of transfer factor for opportunistic infections in cancer patients.
Although supportive care during therapy of patients with malignancies has improved, infection remains the major cause of death in these patients. The problem of "opportunistic" infections is becoming more apparent as better antibiotics are found. The control of these infections depends in part on mechanisms of cell-mediated immunity. It has been demonstrated that delayed-type hypersensitivity can be transferred from one person to another. Therefore, we used transfer factor in the treatment of 15 patients, most with leukemia, who had fungal, viral, or mycobacterial infections that were not responding to conventional therapy. Seven of ten evaluable patients had therapeutic control of their infections while receiving transfer factor. Transfer factor appears to have contributed to these clinical improvements and is a modality of treatment that deserves further investigation.
D000293:Adolescent; D000328:Adult; D001228:Aspergillosis / Q000628:therapy; D002177:Candidiasis / Q000150:complications / Q000628:therapy*; D005260:Female; D006566:Herpesviridae Infections / Q000150:complications / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007938:Leukemia / Q000150:complications* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009164:Mycobacterium Infections / Q000628:therapy; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor